603309 Well Lead Medical
- 11.92
- +0.05+0.42%
Well Lead Medical News
Weili Healthcare (603309): Significant improvement in overseas business and increased profitability
Weili Healthcare (603309): Actively explore overseas markets with high dividends to give back to shareholders
Weili Healthcare (603309): 23Q4 performance growth exceeded expectations and accelerated overseas market development
Weili Medical (603309): Maintain steady operation and continue to consolidate business
Weili Medical (603309): Medical catheter faucet with continuously advanced products
Weili Medical (603309): Deepening reforms and assembling domestic medical catheters before starting
Weili Healthcare (603309): Domestic sales continue to grow, short-term pressure on export sales does not change long-term development potential
Weili Healthcare (603309) 2023 Semi-Annual Report Review: Domestic Revenue Achieves Relatively Rapid Growth, Overseas Revenue Growth Under Pressure
Weili Healthcare (603309): Domestic sales have achieved relatively rapid growth and profitability continues to improve
Weili Healthcare (603309): Overseas business is under short-term pressure, and domestic growth has maintained relatively rapid growth
Weili Medical (603309) 2022 Report and 2023 Quarterly Report Reviews: Outstanding overseas performance in '22, benefiting from diagnosis and treatment in '23, can be expected to resume domestic business growth
Weili Healthcare (603309): Rapid Performance Growth Achieves Stable In-depth Marketing and Product Upgrades Ensure Sustainable Development
Weili Medical (603309): Catheter drives revenue growth in 2022, deepening marketing in the domestic market+recovery in post-epidemic surgery volume is expected to grow rapidly
Deepin* Company* Weili Medical (603309): Domestic medical catheter leader starts a new journey
Weili Medical (603309) Company Review: Predicting rapid growth in performance and two-wheel drive growth in domestic and foreign sales
Weili Medical (603309) Review Report: The company issued an annual pre-increase announcement excluding the impact of equity incentive expenses, net profit of non-return to the mother increased 60% year-on-year
Weili Healthcare (603309): Performance Growth Exceeds Expectations, Profitability Continues to Improve
Weili Medical (603309): the disturbance of the epidemic gradually fades and the scale effect promotes the deduction of non-net profit to increase by 65.20% compared with the same period last year.
Weili Medical (603309): performance continues to exceed expectations, gross profit margin increases, cost reduction and efficiency boost profitability
Weili Medical (603309): 57% increase in export sales exceeded expectations, driving 77% high growth in the company's performance in the first half of the year
Analysis
Price Target
No Data
